Nordicus Partners Corp(NORD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 2 at 5:39 PM ET (Korea 11/3 07:39)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.27 | Insider Own | 66.79% | Shs Outstand | 19.2M | Perf Week | -8% |
| Market Cap | 0.07B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 6.5M | Perf Month | -8.21% |
| Enterprise Value | 0.07B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | - | Perf Quarter | 63.56% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | - | Perf Half Y | 3.36% |
| Sales | 0.00B | P/B | 1.15 | EPS next 5Y | - | ROA | -6.8% | Short Interest | - | Perf YTD | -26.4% |
| Book/sh | 3.21 | P/C | 7155.47 | EPS past 3/5Y | 75.08% 47.92% | ROE | -8.06% | 52W High | -28.54% ($5.15) | Perf Year | -26.4% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | -8.23% | 52W Low | 148.65% ($1.48) | Perf 3Y | -54% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 19.52% | Gross Margin | - | Volatility(W/M) | 20.96% 8.96% | Perf 5Y | -63.65% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.47 | Perf 10Y | 67.99% |
| Dividend Ex-Date | 2020/4/24 | Quick Ratio | 0.18 | EPS Q/Q | -70.2% | Profit Margin | - | RSI (14) | 46.25 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.18 | Sales Q/Q | - | SMA20 | -9.71% ($4.08) | Beta | -1.34 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | 2.08% ($3.61) | Rel Volume | 4.82 | Prev Close | $4.91 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -7.5% ($3.98) | Avg Volume(3M) | 0.01M | Price | $3.68 |
| IPO | 1996/6/12 | Option/Short | No/Yes | Trades | 314 | Volume | 35,801 | Change | -25.08% |
NORDNordicus Partners Corp | NASD | Biotechnology 🧬 A biotech company headquartered in Beverly Hills, California, USA, that operates both a holding company and a business accelerating the connection of Northern European life science companies to the US market. Starting with oral diseases, the company develops therapeutics in the fields of inflammation and immune regulation, and maintains three subsidiaries in Denmark: Orocin, Bioconvert, and Novitera.
Over the past 1 year, roughly in the middle
29% below its 1-year high.
Traded more than usual. That is 482% of its average volume.
NORD has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -63.6%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.0%.
Tap to view numbers
It ranks #385 of 597 in the industry
Based on market cap of $72M.
CNXU#383 Conexeu Sciences Inc $74M PER - 
CING#384 Cingulate Inc $73M PER - NORD#385 Nordicus Partners Corp $72M PER - 
MNOV#386 Medicinova Inc $71M PER - 
ACRV#387 Acrivon Therapeutics Inc $69M PER - 
FAQ
What kind of company is NORD?
NORD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NORD?
The market cap of NORD is approximately $72M, ranking 4,665 within its sector.
What is the 52-week high and low for NORD?
NORD has recorded a 52-week high of $5.15 and a low of $1.48.
